254 citations,
September 2014 in “Menopause” The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.
40 citations,
December 2016 in “Journal of Dermatological Treatment” JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
1 citations,
January 2020 in “Skin appendage disorders” Finasteride is safe for hair loss treatment and doesn't increase high-grade prostate cancer risk.
16 citations,
March 2015 in “Clinical Cancer Research” The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.
355 citations,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
6 citations,
December 2022 in “Cell reports” Eating a high-fat fish oil diet caused mice to lose hair due to a specific immune cell activity in the skin linked to a protein called E-FABP.
March 2021 in “Clin-Alert” The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.
18 citations,
March 2006 in “Expert Review of Neurotherapeutics” The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
185 citations,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
72 citations,
January 2011 in “Current Pharmaceutical Design” S5αR inhibitors might help treat schizophrenia and other mental disorders but need more research.
5 citations,
November 2011 in “Expert Review of Dermatology” The document concludes that early diagnosis and a comprehensive treatment plan are crucial for managing hair loss in children, with a focus on both medical and psychological support.
Off-label drug use can be risky but sometimes beneficial when standard treatments fail.
40 citations,
July 2008 in “Drug Discovery Today” Current treatments for male pattern baldness include minoxidil and finasteride, with new options being developed.
1 citations,
January 2017 in “Expert opinion on orphan drugs” Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.
2 citations,
June 2023 in “Indian journal of dermatology, venereology, and leprology” Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
January 2023 in “Skin appendage disorders” Low-dose oral minoxidil may help treat hair loss but is not FDA-approved and can cause side effects like unwanted hair growth and heart issues.
1 citations,
February 2022 in “JAMA Dermatology” Minoxidil and finasteride are FDA-approved treatments for male hair loss, but off-label use of oral minoxidil, dutasteride, and higher doses of finasteride and minoxidil is increasing.
3 citations,
November 2021 in “Journal of The American Academy of Dermatology” Androgenetic alopecia, a genetic disorder affecting up to 50% of adults, is caused by an excessive response to androgens leading to hair follicle shrinkage. Treatments include FDA-approved drugs, other therapies like low-dose oral minoxidil, and hair transplantation.
April 2022 in “Medicina estética” Minoxidil is the only FDA-approved treatment for female hair loss, with other potential treatments needing more research for effectiveness.
1 citations,
August 2021 in “Cosmoderma” Low-dose oral minoxidil is effective and well-tolerated for treating hair loss.
January 2024 in “Expert Opinion on Pharmacotherapy” Low-dose oral minoxidil is effective and safe for treating hair loss in men and women.
5 citations,
January 2014 in “Hospital pharmacy” Using a strong allergy medicine too often on the scalp can cause swelling and inflammation.
7 citations,
April 2012 in “Clinical investigation” Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.
1 citations,
September 2021 in “Pharmaceutics” High-dose finasteride may help treat glioblastoma but needs localized delivery for effectiveness.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
February 2024 in “Cosmoderma” Low-dose oral minoxidil can help treat male and female pattern hair loss, especially in those who can't use topical treatments or have heart health issues.
March 2024 in “Journal of the Dermatology Nurses’ Association” Low-dose oral minoxidil is being revisited as a promising hair loss treatment.
1 citations,
January 2022 in “Journal of The American Academy of Dermatology” Direct-to-consumer teledermatology platforms have financial conflicts of interest and lack proper patient care and follow-up.
39 citations,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
1 citations,
July 2022 in “JEADV Clinical Practice” New and existing treatments for hair loss show promise, with some being more effective for men and others for women.